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Abstract
A subset of GISTs lack mutations in the KIT/PDGFRA or RAS pathways and
yet retain an intact succinate dehydrogensase (SDH) complex. We propose that
these KIT/PDGFRA/SDH/RAS-P WT GIST tumors be designated as quadruple
wild-type (WT) GIST. Further molecular and clinicophatological characteriza-
tion of quadruple WT GIST will help to determine their prognosis as well as
assist in the optimization of medical management, including clinical test of
novel therapies.
Introduction
Approximately, 85–90% of gastrointestinal stromal
tumors (GISTs) in adults harbor mutant KIT or platelet-
derived growth factor receptor alpha (PDGFRA) oncopro-
teins [1]. The remaining adult cases and the vast majority
of pediatric GISTs do not harbor mutations in these
receptors and are often referred to as KIT/PDGFRA wild-
type (WT) GISTs [1, 2]. Amongst the WT GISTs, at least
two other different subgroups with well-defined molecular
hallmarks have been described. Approximately, 15% of
these cases harbor an activating mutation in BRAF, or
more rarely, a RAS gene [3]. In addition, WT GIST can
arise in the context of the syndromic neurofibromatosis
type I (NF1) disease, associated with loss of function of
the NF1 protein due to genomic inactivation of both NF1
alleles [4]. Collectively, GISTs with mutations in BRAF/
RAS or NF1 can be referred to as the RAS-pathway
(RAS-P) mutant GIST.
Between 20% and 40% of KIT/PDGFRA WT GISTs
show loss of function of the succinate dehydrogenase
complex (SDH), manifested by the loss of subunit B
(SDHB) protein expression. These tumors are desig-
nated as SDH-deficient GISTs or SDHB-negative GISTs
based on their immunohistochemical (IHC) status.
Some investigators have designated SDHB IHC-negative
GISTs as type 2 GISTs. Furthermore, SDH-deficient
GISTs have distinctive clinicopathological features
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characteristic pathological, and clinical characteristics,
including a predilection for young women, gastric local-
ization, mixed epithelioid and spindle cell morphology,
diffuse KIT and ANO1 (DOG1) IHC positivity, fre-
quent lymph node metastases, and an indolent course
of disease even when metastases are present [5, 6].
Moreover, the SDHB IHC-negative GIST is character-
ized by over expression of the insulin growth factor 1
receptor (IGF1R) [7, 8]. The most frequent identifiable
molecular events found in SDHB-deficient GISTs are
germline and/or somatic loss-of-function mutations in
any of the four SDH subunits. (A, B, C, or D) [9, 10].
Recently, other molecular events associated with SDH
deficiency have been reported, including genome-wide
DNA hypermethylation and a specific microRNA profile
[11, 12].
Tumors with SDHA mutations comprise the most
common subtype of SDH-deficient GIST, and demon-
strate loss of SDHA protein expression in addition to the
loss of SDHB protein expression [13, 14]. The SDHB
IHC-negative/SDHA IHC-positive subgroup is histologi-
cally similar to SDHA IHC-negative GIST, but with a les-
ser female prevalence. Many of these GISTs arise in the
context of the Carney–Stratakis Syndrome (the dyad of
GIST and paraganglioma), and are characterized by germ-
line SDHB, SDHC or SDHD-inactivating mutations. They
also occur in the context of the Carney Triad (gastric
GIST, paraganglioma, and pulmonary chondroma), which
do not harbor SDHx-mutations [15, 16]. Recently, Haller
et al. have reported hypermethylation of SDHC as a novel
mechanism of tumor development in Carney Triad [17].
KIT/PDGFRA WT GISTs lacking abnormalities of the
SDH complex are SDHB IHC-positive and have been
referred to as type 1 GIST. This SDHB IHC-positive sub-
group includes NF1-mutated GIST, which commonly
present in the small bowel in a multifocal manner and
are negative for IGF1R staining. This subgroup also
includes sporadic KIT/PDGFRA WT GIST arising any-
where in the gastrointestinal tract in adult patients [6].
Based on the above array of molecular markers, it has
become apparent that approximately 5% of all GISTs lack
mutations in the KIT exons 8, 9, 11, 13, 14, 17/PDGFRA
exons 12, 14, 18 or RAS pathways (BRAF exons 11, 15/
RAS exons 2, 3 or NF1), and yet retain an intact SDH
complex (SDHB IHC positive, no mutations of SDHA/B/
C/D).
We propose that these KIT/PDGFRA/SDH/RAS-P WT
GIST tumors be designated as quadruple WT GIST, or
quadruple negative GIST, in contrast to other categories of
GISTs characterized by oncogenic abnormalities of at least
of one of the four pathways (KIT mutant, PDGFRA
mutant, SDH deficient, or RAS/BRAF/NF1 mutant GISTs)
(Fig. 1). The pathogenesis and underlying biology of qua-
druple WT GISTs is currently unknown. Moreover,
descriptive clinical and pathological data for this group
have not been defined. However, the absence of molecular
events in the four known pathways suggests that this
entity represents a completely different type of GIST.
Genome wide studies of gene expression, copy number
variation, and/or transcriptome sequencing may be useful
to better characterize quadruple WT GISTs and to iden-
tify their underlying molecular abnormalities. Given their
rarity, clinical and pathological data should be analyzed
from large series of quadruple WT GIST to help identify
their specific clinicopathological features. Discovering the
novel molecular alterations that characterize quadruple
WT GIST will help to define their clinical behavior/prog-
nosis as well as to aid in the evaluation of conventional
as well as novel GIST medical treatments. As with other
subgroups of GIST, we propose that further specific stud-
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Figure 1. Current characterization of KIT/PDGFRA WT GIST. *More data should be accumulated.
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